GAM
BIO icon

Groupama Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Groupama Asset Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,175
Closed -$584K – 417
2024
Q3 		$584K Buy
+2,175
New +$691K 0.02% 333
2024
Q2 		– Sell
-996
Closed -$838K – 456
2024
Q1 		$838K Sell
996
-1,126
-53% -$370K 0.02% 332
2023
Q4 		$685K Buy
+2,122
New +$665K 0.02% 317

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Groupama Asset Management's BIO Position: Q4 2024 in Review

Groupama Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2024, closing a stake of 2,175 shares — an estimated $584K sold.

Groupama Asset Management first reported a position in BIO in Q4 2023 and held it in 3 quarters. The position peaked at $838K in Q1 2024. 456 funds tracked by Wall St. Rank hold BIO as of Q4 2024.

  • Groupama Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2024 after selling out during the quarter.
  • Groupama Asset Management sold 2,175 Bio-Rad Laboratories Class A shares in Q4 2024, an estimated $584K.
  • Groupama Asset Management first reported a position in Bio-Rad Laboratories Class A in Q4 2023 and held it in 3 quarters.
  • Groupama Asset Management's Bio-Rad Laboratories Class A position peaked at $838K in Q1 2024.
  • 456 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2024.

Based on Groupama Asset Management's 13F filing for Q4 2024, filed 12 Feb 2025.